in silico adme prediction
Recently Published Documents


TOTAL DOCUMENTS

31
(FIVE YEARS 8)

H-INDEX

8
(FIVE YEARS 2)

RSC Advances ◽  
2021 ◽  
Vol 11 (44) ◽  
pp. 27659-27673
Author(s):  
Mohamed A. S. Badawy ◽  
Eman K. A. Abdelall ◽  
EL-Shaymaa EL-Nahass ◽  
Khaled R. A. Abdellatif ◽  
Hamdy M. Abdel-Rahman

A novel series of benzimidazole derivatives wherein 4-(methylsulfonyl) phenyl pharmacophore attached via its C-2 position was designed and synthesized.


2019 ◽  
Vol 16 (9) ◽  
pp. 815-820 ◽  
Author(s):  
Rim Malek ◽  
Bernard Refouvelet ◽  
Mohamed Benchekroun ◽  
Isabel Iriepa ◽  
Ignacio Moraleda ◽  
...  

Background: Many factors are involved in Alzheimer’s Disease (AD) such as amyloid plaques, neurofibrillary tangles, cholinergic deficit and oxidative stress. To counter the complexity of the disease the new approach for drug development is to create a single molecule able to act simultaneously on different targets. Objective: We conceived eight drug likeliness compounds targeting the inhibition of cholinesterases and the scavenging of radicals. Methods: We synthesised the new molecules by the Passerini multicomponent reaction and evaluated their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) as well as their antioxidant activities by the Oxygen Radical Absorbance Capacity (ORAC) assay. The lipinski’s rule for drug likeness and in silico ADME prediction was also performed. Results: Compounds 4f [IC50 (EeAChE) = 0.30 μM; IC50 (eqBuChE) = 0.09 μM; ORAC = 0.64 TE] and 4h [IC50 (EeAChE) = 1 μM; IC50 (eqBuChE) = 0.03 μM; ORAC = 0.50 TE] were identified as hits for further development. Conclusion: The Passerini reaction allowed us the facile synthesis of ditarget molecules of interest for the treatment of AD.


Sign in / Sign up

Export Citation Format

Share Document